Novartis hopes new data will help it take on Pfizer. It probably won’t - STAT

Novartis hopes new data will help it take on Pfizer. It probably won’t - STAT

STAT Plus: Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t

By MATTHEW HERPER

ANNIE CAVANAGH/WELLCOME

Kisqali, a breast cancer drug from Novartis, dramatically extended survival in younger women who developed the most common form of breast cancer.

READ MORE